Ab­b­Vie, J&J block­buster Im­bru­vi­ca rakes in 11th FDA ap­proval, as com­peti­tors work on erod­ing fran­chise

Ab­b­Vie and J&J’s mar­ket-lead­ing Im­bru­vi­ca, the orig­i­nal BTK in­hibitor, con­tin­ues to rake in ap­provals, while com­pe­ti­tion in the class of drugs heats up.

On Tues­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER